Nexavar 200 mg Alternative – Hepanib (Sorafenib) 200 mg Tablet | Everest Pharmaceuticals
Hepanib 200 mg (Sorafenib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Nexavar (Bayer). It belongs to the multikinase inhibitor class and is used in selected liver, kidney and thyroid cancers.
Active ingredient: Sorafenib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Hepanib 200 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Sorafenib. It is listed here as a same-ingredient branded option for people researching Nexavar, a reference brand associated with Bayer. Hepanib and Nexavar must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 200 mg strength.
Hepanib vs. Nexavar – Originator / Reference Brand Comparison
Nexavar is a widely recognized reference brand for Sorafenib associated with Bayer. Hepanib is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Hepanib is manufactured by Bayer, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Sorafenib
Strength: 200 mg
Dosage form: Tablet
Pharmacological class: multikinase inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Sorafenib is used in selected liver, kidney and thyroid cancers. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Sorafenib Works
Sorafenib is a multikinase inhibitor. In general, it blocks RAF and angiogenesis-associated receptor kinases. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 200 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Sorafenib include: hand-foot reactions, diarrhea, high blood pressure and bleeding. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Sorafenib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include hand-foot reactions, diarrhea, high blood pressure and bleeding. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Sorafenib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Sorafenib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Hepanib Listed as an Alternative to Nexavar?
This listing helps customers identify an Everest Pharmaceuticals product containing Sorafenib while researching Nexavar. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Hepanib
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Nexavar
Reference company: Bayer
Generic ingredient: Sorafenib
Strength: 200 mg
Dosage form: Tablet
Therapeutic class: multikinase inhibitor
Frequently Asked Questions
What is Hepanib 200 mg?
It is an Everest Pharmaceuticals tablet containing Sorafenib 200 mg.
Is Hepanib the same as Nexavar?
They are presented as brands associated with Sorafenib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Sorafenib used for?
Sorafenib is used in selected liver, kidney and thyroid cancers, subject to the applicable label and clinical assessment.
How does Sorafenib work?
It blocks RAF and angiogenesis-associated receptor kinases.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Sorafenib |
|---|---|
| Strength | 200 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 28 tablets |
Related products
Balversa 4 mg Alternative – Erdarixen (Erdafitinib) 4 mg Tablet | Everest Pharmaceuticals
Erdarixen 4 mg (Erdafitinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Balversa (Janssen). It belongs to the FGFR inhibitor class and is used in selected FGFR-altered urothelial cancer.
Active ingredient: Erdafitinib
Strength: 4 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lynparza 150 mg Alternative – Olanib (Olaparib) 150 mg Tablet | Everest Pharmaceuticals
Olanib 150 mg (Olaparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lynparza (AstraZeneca / MSD). It belongs to the PARP inhibitor class and is used in selected ovarian, breast, pancreatic and prostate cancers.
Active ingredient: Olaparib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.